Obesity is a public health problem also a genetic and chronic metabolic disease which involves accumulation of excessive or abnormal fat in the body. Chronic conditions such as hypertension, cardiovascular diseases, diabetics, ventilatory failure, obstructive sleep apnea, cancer, and others are associated with obesity. Increasing prevalence of obesity among children and adults is affectation a threat and developing nations also it has a major impact on population longevity and health related expense.
MARKET DYNAMICS
Changing lifestyle leading to decrease in exercise practice among people, product developments, and increase in the obesity population is expected to drive the demand for anti-obesity drugs in the near future. However, the availability of alternative therapies and the possible side effects of anti-obesity drugs are expected to hamper the market growth.
MARKET SCOPE
The "Anti-Obesity Prescription Drugs Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of anti-obesity prescription drugs market with detailed market segmentation by drug class, mechanism of action, and distribution channel. The anti-obesity prescription drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in anti-obesity prescription drugs market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The anti-obesity prescription drugs market is segmented on the basis of drug class, mechanism of action, and distribution channel. Based on drug class, the market is segmented as bupropion and naltrexone, orlistat, lorcaserin, phentermine and topiramate, and liraglutide. Based on mechanism of action, the market is segmented as peripherally acting drugs and centrally acting drugs. By distribution channel, the market is segmented as hospital pharmacy, retail pharmacy, and online pharmacy.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the anti-obesity prescription drugs market based onvarious segments. It also provides market size and forecast estimates from year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The anti-obesity prescription drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting anti-obesity prescription drugs market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the anti-obesity prescription drugs market in these regions.
MARKET PLAYERS
The report covers key developments in the anti-obesity prescription drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from anti-obesity prescription drugs market are anticipated to have lucrative growth opportunities in the future with the rising demand for anti-obesity prescription drugs in the global market. Below mentioned is the list of few companies engaged in the anti-obesity prescription drugs market.
The report also includes the profiles of key players in anti-obesity prescription drugs market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and drug class, mechanism of action, and distribution channel s offered, financial information of last 3 years, key development in past five years.
- BRISTOL-MYERS SQUIBB CO.
- TAKEDA PHARMACEUTICAL
- EISAI COMPANY
- GLAXOSMITHKLINE PLC
- PFIZER INC
- SHIONOGI USA INC
- VIVUS INC
- ZAFGEN INC
- NORGINE BV
- BOEHRINGER INGELHEIM GMBH.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.